# GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
Canonical URL: https://biopharmsignal.com/news/GHRS/gh-research-announces-novel-therapies-symposium-presentation-and-posters-at-the-2025-ecnp-congress
Ticker: GHRS
Company: GH Research
Source: GH Research
Published: 2025-10-09 11:00 EST
Original Source URL: https://investor.ghres.com
## Summary

DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Novel Therapies Symposium Presentation

## Article Body
DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Novel Therapies Symposium Presentation
## Recent Company News
- 2026-06-04 11:00 EST — [GH Research Announces Publication of Phase 2a Postpartum Depression Results](https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2a-postpartum-depression-results) — Source: GH Research
- 2026-05-14 11:00 EST — [GH Research Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GHRS/gh-research-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: GH Research
- 2026-04-29 12:00 EST — [GH Research Announces Pricing of $117.5 Million Underwritten Offering](https://biopharmsignal.com/news/GHRS/gh-research-announces-pricing-of-117-5-million-underwritten-offering) — Source: GH Research
- 2026-04-20 13:00 EST — [GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness](https://biopharmsignal.com/news/GHRS/gh-research-welcomes-white-house-executive-order-to-accelerate-medical-treatments-for-serious-mental-illness) — Source: GH Research
- 2026-03-25 15:11 EST — [GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD](https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2b-results-for-mebufotenin-gh001-in-jama-psychiatry-and-reports-new-finding-of-severity-independent-efficacy-in-trd) — Source: GH Research
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)